References
- Berdelou A, Borget I, Godbert Y, et al. Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid. 2018;28(1):72–78. DOI:https://doi.org/10.1089/thy.2017.0205.
- Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–2899. DOI:https://doi.org/10.1210/jc.2005-2838.
- Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498–505. DOI:https://doi.org/10.1210/jc.2005-1534.
- Deandreis D, Leboulleux S, Dromain C, et al. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology. 2011;258(1):270–276. DOI:https://doi.org/10.1148/radiol.10092440.
- Brose MS, Smit J, Capdevila J, et al. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther. 2012;12(9):1137–1147. DOI:https://doi.org/10.1586/era.12.96.
- Rivera M, Ghossein RA, Schoder H, et al. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer. 2008;113(1):48–56. DOI:https://doi.org/10.1002/cncr.23515.
- de la Fouchardiere C, Oussaid N, Derbel O, et al. Does molecular genotype provide useful information in the management of radioiodine refractory thyroid cancers? Results of a retrospective study. Target Oncol. 2016;11(1):71–82. DOI:https://doi.org/10.1007/s11523-015-0380-y.
- Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th edn. Edited by: Wiley. 2017;51.
- Hiltzik D, Carlson DL, Tuttle RM, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer. 2006;106(6):1286–1295. DOI:https://doi.org/10.1002/cncr.21739.
- Agrawal N, Akbani R, Aksoy B; Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–690. DOI:https://doi.org/10.1016/j.cell.2014.09.050 .
- Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):2307.
- Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052–1066. DOI:https://doi.org/10.1172/JCI85271.
- Soares P, Povoa AA, Melo M, et al. Molecular pathology of non-familial follicular epithelial-derived thyroid cancer in adults: from RAS/BRAF-like tumor designations to molecular risk stratification. Endocr Pathol. 2021;32(1):44–62. DOI:https://doi.org/10.1007/s12022-021-09666-1.
- Ricarte-Filho JC, Li S, Garcia-Rendueles ME, et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest. 2013;123(11):4935–4944. DOI:https://doi.org/10.1172/JCI69766.
- Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121(12):4700–4711. DOI:https://doi.org/10.1172/JCI46382.
- Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92(7):2840–2843. DOI:https://doi.org/10.1210/jc.2006-2707.
- Liu R, Bishop J, Zhu G, et al. Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer. JAMA Oncol. 2017;3(2):202–208. DOI:https://doi.org/10.1001/jamaoncol.2016.3288.
- Liu J, Liu R, Shen X, et al. The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. J Nucl Med. 2020;61(2):177–182. DOI:https://doi.org/10.2967/jnumed.119.227652.
- Sabra MM, Dominguez JM, Grewal RK, et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab. 2013;98(5):E829–836. DOI:https://doi.org/10.1210/jc.2012-3933.
- Deandreis D, Al Ghuzlan A, Leboulleux S, et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer. 2011;18(1):159–169. DOI:https://doi.org/10.1677/ERC-10-0233.
- Sapuppo G, Hartl D, Fresneau B, et al. Differentiated thyroid cancer in children and adolescents: long term outcome and risk factors for persistent disease. Cancers (Basel). 2021;14(1):13. DOI:https://doi.org/10.3390/cancers14010013.
- Deandreis D, Rubino C, Tala H, et al. Comparison of empiric versus whole-body/-blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer. J Nucl Med. 2017;58(5):717–722. DOI:https://doi.org/10.2967/jnumed.116.179606.
- Tuttle RM, Ahuja S, Avram AM, et al. Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid cancer: a joint statement from the American thyroid association, the European association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the European thyroid association. Thyroid. 2019;29(4):461–470. DOI:https://doi.org/10.1089/thy.2018.0597.
- Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2(5):356–358. DOI:https://doi.org/10.1016/S2213-8587(13)70215-8.
- Carhill AA, Litofsky DR, Ross DS, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012. J Clin Endocrinol Metab. 2015;100(9):3270–3279. DOI:https://doi.org/10.1210/JC.2015-1346.
- Farooki A, Leung V, Tala H, et al. Skeletal-related events due to bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab. 2012;97(7):2433–2439.
- Barat M, Tselikas L, de Baere T, et al. Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma. Eur J Radiol. 2019;119:108650.
- Deandreis D, Maillard A, Zerdoud S, et al. RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2021;48(10):3238–3249. DOI:https://doi.org/10.1007/s00259-021-05229-y.
- Bonichon F, de Baere T, Berdelou A, et al. Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network. Endocrine. 2021;72(3):798–808. DOI:https://doi.org/10.1007/s12020-020-02580-2.
- Lamartina L, Ippolito S, Danis M, et al. Antiangiogenic tyrosine kinase inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer. J Clin Endocrinol Metab. 2016;101(7):2733–2741. DOI:https://doi.org/10.1210/jc.2015-4391.
- Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21(7):707–716. DOI:https://doi.org/10.1089/thy.2010.0355.
- Sabra MM, Sherman E, Tuttle RM. Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy. Clin Endocrinol (Oxf). 2019;90(4):617–622.
- Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. 2000;92:205–216.
- Sabra MM, Sherman EJ, Tuttle RM. Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. Cancer. 2017;123(15):2955–2964.
- Tuttle RM, Brose MS, Grande E, et al. Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. Best practice & research. J Clin Endocrinol Metab. 2017;31:295–305.
- Robinson B, Schlumberger M, Wirth LJ, et al. Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab. 2016;101(11):4103–4109. DOI:https://doi.org/10.1210/jc.2015-3989.
- Lamartina L, Godbert Y, Nascimento C, et al. Locally unresectable differentiated thyroid cancer: outcomes and perspectives. Endocrine. 2020;69(1):133–141. DOI:https://doi.org/10.1007/s12020-020-02245-0.
- Terroir M, Borget I, Bidault F, et al. The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2017;44(4):638–646. DOI:https://doi.org/10.1007/s00259-016-3551-x.
- Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):464–468.
- Albero A, Lopez JE, Torres A, et al. Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. Endocr Relat Cancer. 2016;23(2):R71–84. DOI:https://doi.org/10.1530/ERC-15-0194.
- Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214. DOI:https://doi.org/10.1089/thy.2009.0110.
- Haugen BR, Alexander EK, Bible KC, et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 . 2015; 26:1–133.
- Filetti S, Durante C, Hartl D, et al., Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(12):1856–1883. . https://doi.org/10.1093/annonc/mdz400.
- Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328. (London, England). DOI:https://doi.org/10.1016/S0140-6736(14)60421-9.
- Schlumberger M, Tahara M, Wirth LJ. Lenvatinib in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):1868. DOI:https://doi.org/10.1056/NEJMoa1406470.
- Brose MS, Worden FP, Newbold KL, et al. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol. 2017;35(23):2692–2699. DOI:https://doi.org/10.1200/JCO.2016.71.6472.
- Taylor MH, Takahashi S, Capdevila J, et al. Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid. 2021;31(8):1226–1234. DOI:https://doi.org/10.1089/thy.2020.0779.
- Tahara M, Kiyota N, Hoff AO, et al. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. Oxford, England: 1990. 2021;147:51–57. DOI:https://doi.org/10.1016/j.ejca.2020.12.032.
- Brose M, Panaseykin Y, Konda B, et al. A multicenter, randomized, double-blind, phase 2 study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg. Asia: European Society for Medical Oncology; 2020.
- Locati LD, Piovesan A, Durante C, et al. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur J Cancer. Oxford, England: 1990. 2019;118:35–40. DOI:https://doi.org/10.1016/j.ejca.2019.05.031.
- Aydemirli MD, Kapiteijn E, Ferrier KRM, et al. Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: dutch real-life data. Eur J Endocrinol. 2020;182(2):131–138. DOI:https://doi.org/10.1530/EJE-19-0763.
- Masaki C, Sugino K, Saito N, et al. Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences. Thyroid. 2020;30(2):214–221. DOI:https://doi.org/10.1089/thy.2019.0221.
- Rendl G, Sipos B, Becherer A, et al. Real-world data for lenvatinib in radioiodine-refractory differentiated thyroid cancer (RELEVANT): a retrospective multicentric analysis of clinical practice in Austria. Int J Endocrinol. 2020;2020:8834148.
- Koehler VF, Berg E, Adam P, et al. Real-world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. Thyroid. 2021;31(10):1531–1541. DOI:https://doi.org/10.1089/thy.2021.0091.
- Marotta V, Ramundo V, Camera L, et al. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol (Oxf). 2013;78(5):760–767. DOI:https://doi.org/10.1111/cen.12057.
- Brose MS, Robinson B, Sherman SI, et al., Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(8):1126–1138. . https://doi.org/10.1016/S1470-2045(21)00332-6.
- Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897–905. DOI:https://doi.org/10.1016/S1470-2045(12)70335-2.
- Bastholt L, Schlumberger M, Fagin JA. Vandetanib in patients with locally advanced or metastatic differentiated thyroid cancer who are refractory or unsuitable for radioiodine therapy: a Phase III study (VERIFY). 2016 ETA meeting, Copenhagen. 2016.
- Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708–4713. DOI:https://doi.org/10.1200/JCO.2007.15.9566.
- Locati LD, Licitra L, Agate L, et al. Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014;120(17):2694–2703. DOI:https://doi.org/10.1002/cncr.28766.
- Capdevila J, Trigo JM, Aller J, et al. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). Eur J Endocrinol. 2017;177(4):309–317. DOI:https://doi.org/10.1530/EJE-17-0243.
- Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11(10):962–972. DOI:https://doi.org/10.1016/S1470-2045(10)70203-5.
- de la Fouchardiere C, Godbert Y, Dalban C, et al. Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: final results of the randomised, multicenter, open-label phase II trial PAZOTHYR. Eur J Cancer. Oxford, England: 1990. 2021;157:153–164. DOI:https://doi.org/10.1016/j.ejca.2021.07.029.
- Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res off J Am Assoc Cancer Res. 2010;16(21):5260–5268. DOI:https://doi.org/10.1158/1078-0432.CCR-10-0994.
- Lin Y-S, Qin S-K, Li Z-Y, et al. LBA89 A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. Ann Oncol. 2020;31:1215.
- Chi Y, Gao M, Zhang Y, et al. LBA88 Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phase II trial. Ann Oncol. 2020;31:S1215.
- Nervo A, Ragni A, Piovesan A, et al. Quality of life during treatment with lenvatinib for thyroid cancer: the patients’ perspective beyond the medical evaluation. Eur Thyroid J. 2021;10(1):65–71. DOI:https://doi.org/10.1159/000508186.
- Giani C, Valerio L, Bongiovanni A, et al. Safety and quality-of-life data from an italian expanded access program of lenvatinib for treatment of thyroid cancer. Thyroid. 2021;31(2):224–232. DOI:https://doi.org/10.1089/thy.2020.0276.
- Tahara M, Brose MS, Wirth LJ, et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. Oxford, England: 1990. 2019;106:61–68. DOI:https://doi.org/10.1016/j.ejca.2018.10.002.
- Valerio L, Giani C, Agate L, et al. Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer. Eur Thyroid J. 2021;10(5):399–407. DOI:https://doi.org/10.1159/000514182.
- Doebele RC, Drilon A, Paz-Ares L, et al., Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271–282. . https://doi.org/10.1016/S1470-2045(19)30691-6.
- Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK Fusion–Positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. DOI:https://doi.org/10.1056/NEJMoa1714448.
- Hong DS, DuBois SG, Kummar S, et al., Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531–540. . https://doi.org/10.1016/S1470-2045(19)30856-3.
- Cabanillas ME, Drilon A, Farago AF, et al. Larotrectinib treatment of advanced TRK fusion thyroid cancer. Annals clin Oncol. 2020;31:S1086.
- Wirth LJ, Sherman E, Robinson B, et al., Efficacy of selpercatinib in RET -altered thyroid cancers. N Engl J Med. 2020;383(9):825–835. . https://doi.org/10.1056/NEJMoa2005651.
- Bradford D, Larkins E, Mushti SL, et al. FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin Cancer Res off J Am Assoc Cancer Res. 2021;27(8):2130–2135. DOI:https://doi.org/10.1158/1078-0432.CCR-20-3558.
- Subbiah V, Hu MI, Wirth LJ, et al., Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491–501. . https://doi.org/10.1016/S2213-8587(21)00120-0.
- Kim J, Bradford D, Larkins E, et al. FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin Cancer Res off J Am Assoc Cancer Res. 2021;27(20):5452–5456. DOI:https://doi.org/10.1158/1078-0432.CCR-21-0967.
- Brose MS, Cabanillas ME, Cohen EEW, et al. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. The Lancet Oncology. 2016;17(9):1272–1282. DOI:https://doi.org/10.1016/S1470-2045(16)30166-8.
- Falchook GS, Millward M, Hong D, et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF -mutant thyroid cancer. Thyroid. 2015;25(1):71–77. DOI:https://doi.org/10.1089/thy.2014.0123.
- Shah MH, Wei L, Wirth L, et al. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J clin oncol. 2017;35(15_suppl):6022. DOI:https://doi.org/10.1200/JCO.2017.35.15_suppl.6022.
- Dunn LA, Sherman EJ, Baxi SS, et al., Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. J Clin Endocrinol Metab. 2019;104(5):1417–1428. . https://doi.org/10.1210/jc.2018-01478.
- Leboulleux S, Do Cao C, Zerdoud S, et al. MERAIODE: a redifferentiation phase II trial with trametinib and dabrafenib followed by radioactive iodine administration for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a BRAFV600E mutation (NCT 03244956). J Endocr Soc. 2021;5(Supplement_1):A876. DOI:https://doi.org/10.1210/jendso/bvab048.1789.
- Leboulleux S, Benisvy D, Taieb D, et al. MERAIODE: a redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation. ESMO 2021.
- Rothenberg SM, McFadden DG, Palmer EL, et al. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res off J Am Assoc Cancer Res. 2015;21(5):1028–1035. DOI:https://doi.org/10.1158/1078-0432.CCR-14-2915.
- Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623–632. DOI:https://doi.org/10.1056/NEJMoa1209288.
- Sherman EJ, Su YB, Lyall A, et al. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. Thyroid. 2013;23(5):593–599. DOI:https://doi.org/10.1089/thy.2012.0393.
- Tchekmedyian V, Dunn L, Sherman E, et al. Enhancing radioiodine incorporation in BRAF -mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial. Thyroid. 2022;32(3):273–282. DOI:https://doi.org/10.1089/thy.2021.0565.
- Leboulleux S, Dupuy C, Lacroix L, et al. Redifferentiation of a BRAF K601E -mutated poorly differentiated thyroid cancer patient with dabrafenib and trametinib treatment. Thyroid. 2019;29(5):735–742. DOI:https://doi.org/10.1089/thy.2018.0457.
- Groussin L, Clerc J, Huillard O. Larotrectinib-enhanced radioactive iodine uptake in advanced thyroid cancer. N Engl J Med. 2020;383(17):1686–1687.
- Groussin L, Bessiene L, Arrondeau J, et al. Selpercatinib-enhanced radioiodine uptake in RET-rearranged thyroid cancer. Thyroid. 2021. DOI:https://doi.org/10.1089/thy.2021.0144.
- Saqcena M, Leandro-Garcia LJ, Maag JLV, et al. SWI/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies. Cancer Discov. 2021;11(5):1158–1175. DOI:https://doi.org/10.1158/2159-8290.CD-20-0735.
- Borson-Chazot F, Dantony E, Illouz F, et al. Effect of buparlisib, a pan-class I PI3K inhibitor, in refractory follicular and poorly differentiated thyroid cancer. Thyroid. 2018;28(9):1174–1179. DOI:https://doi.org/10.1089/thy.2017.0663.
- Hanna GJ, Busaidy NL, Chau NG, et al. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res off J Am Assoc Cancer Res. 2018;24(7):1546–1553. DOI:https://doi.org/10.1158/1078-0432.CCR-17-2297.
- Schneider TC, de Wit D, Links TP, et al. Everolimus in patients with advanced follicular-derived thyroid cancer: results of a phase II clinical trial. J Clin Endocrinol Metab. 2017;102(2):698–707. DOI:https://doi.org/10.1210/jc.2016-2525.
- Sherman E, Foster NR, Su YB, et al. Randomized Phase II study of sorafenib with or without everolimus in patients with radioactive refractory Hurthle cell thyroid cancer (ITOG 1706). ASCO 2021.
- Mehnert JM, Varga A, Brose M, et al. Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. J clin oncol. 2016;34(15_suppl):6091. DOI:https://doi.org/10.1200/JCO.2016.34.15_suppl.6091.
- Leboulleux S, Godbert Y, Penel N, et al. Benefits of pembrolizumab in progressive radioactive iodine refractory thyroid cancer: results of the AcSé Pembrolizumab study from Unicancer. ASCO 2021.
- Haugen B, French JD, Worden FP, et al. Lenvatinib plus pembrolizumab combination therapy in patients with radioactive iodine refractory (RAIR) progressive differentiated Thyroid cancer (DTC): results of a multicenter phase II International Thyroid Oncologic Group Trial. ASCO 2020.
- Haugen B, French JD, Worden FP, et al. Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: results of a multicenter phase II International Thyroid Oncology Group Trial. ESMO 2020.
- Zanchetta M, Iacuzzi V, Posocco B, et al. A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring. PloS one. 2021;16(10):e0259137. DOI:https://doi.org/10.1371/journal.pone.0259137.
- Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31–42.
- Subbiah V, Mi-n H, Gainor JF, et al. Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. J clin oncol. 2020;38(15_suppl):109. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.109.